BHV3000-312 – Migraine (With or Without Aura) in Children and Adolescents.

BHV3000-312- Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents.

$
This study is a 58-week study for people who complete the study BHV3000-311 to receive open-label Rimegepant.
$

This trial is accepting new patients aged 12-17.

$

Basic Enrollment Criteria:

  • 12-17 years of age
  • Have had a history of migraines for at least the last 6 months
  • Willing to comply with study visits and requirements
  • Completed trial BHV3000-311
$

The age group of 6-11 is not open for enrollment at this time but will be in the future.

$

Basic Enrollment Criteria:

  • 12-17 years of age
  • Have had a history of migraines for at least the last 6 months
  • Willing to comply with study visits and requirements
  • Completed trial 3110-305-002

Participate In This Study